Apollo invests $3.4B in Bayer’s LARC business
The carve-out includes a global portfolio of intrauterine devices and contraceptive implants spanning hormone-based and non-hormonal options used by millions of women.
Takeaways
- Bayer's LARC Business is a global long-acting reversible contraception portfolio that includes intrauterine devices and contraceptive implants.
- Apollo Global Management is acquiring Bayer's LARC Business.
- Disclosed scale includes $3.4 billion.
Apollo invested $3.4 billion in Bayer’s long-acting reversible contraception business, carving out a portfolio of intrauterine devices and contraceptive implants from Bayer’s pharmaceutical division.
The transaction establishes the LARC unit as an independent women’s health platform focused on hormone-based and non-hormonal reproductive health products used across global markets.
Bayer said the carve-out gives the business dedicated ownership and capital for its next phase of growth.
Get Buyout Desk email updates.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up on the site. Email updates are not on a fixed schedule.